This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.
Billions of dollars have been invested in companies promising to “revolutionise pharma R&D” through the application of artificial intelligence – but it is now clear that global pharmacompanies, and not just tech bro’s, are buying into the claims. And there is no doubt that there is plenty of room for improvement.
As a small biotech company with new technology at the frontier of the known drug discovery universe, it may feel like you’re charting a course alone in a dark, cold, and empty void with hailing frequencies open, but with no incoming transmissions. But you would be wrong.
Which high throughput screening (HTS) approach is the most productive in finding hits for drugdevelopment: target-based or phenotypic? By a 3:1 margin, PerkinElmer found top Pharma screens for a specific target. Smallmolecules are making a comeback. It is an ongoing debate.
There, I supported AI-enabled DD efforts in their smallmolecule portfolio. big pharma or startups/spin off? thanks Big pharma experienced is very well respected within biotech or small-startups. Where do you enjoy more to work? What pro/cons?
Can you elaborate on how the platform allows your company to tailor therapy? We can link smallmoleculedrugs to a payload that would enter in the cell and kill it. We have the capability of different types of targets, whether smallmolecules or antibodies. Ahmed Hamby: We also have a very cool modification.
Micro- and macroalgae from both marine and fresh water produce smallmolecules and secondary metabolites with aggregative, anti-inflammatory, antioxidant, antimicrobial, anti-viral and anti-tumoural bioactivities. Examples include phlorotannins from brown seaweeds and smallmolecules like terpenoids and peptides, found in microalgae.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content